Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.

American journal of preventive cardiology·2026
Same author

Capturing multi-disease states on a spectrum with machine learning and routine clinical data.

Med (New York, N.Y.)·2026
Same author

Remnant cholesterol - The transition from biomarker to risk factor.

Atherosclerosis·2026
Same author

Inclisiran in CKD: A Therapeutic Answer to a Persistent Treatment Gap.

Journal of the American Society of Nephrology : JASN·2026
Same author

Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.

The Journal of clinical investigation·2026
Same author

Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.

American journal of preventive cardiology·2026

Related Experiment Video

Updated: Jun 6, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Recombinant high-density lipoprotein formulations.

Esad Vucic1, Robert S Rosenson

  • 1Translational and Molecular Imaging Institute, Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.

Current Atherosclerosis Reports
|November 9, 2010
PubMed
Summary

Novel recombinant high-density lipoprotein (HDL) therapies show promise for reducing residual cardiovascular disease (CVD) risk. These therapies mimic native HDL to improve cholesterol efflux, but require further clinical trials for atherosclerosis and CVD events.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
08:24

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

Related Experiment Videos

Last Updated: Jun 6, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
08:24

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • High-density lipoprotein cholesterol (HDL-C) is a biomarker for residual cardiovascular disease (CVD) risk in patients on low-density lipoprotein cholesterol (LDL-C) lowering therapies.
  • Limited evidence exists for increasing low HDL-C levels, with confounding metabolic interactions between very low-density lipoprotein (VLDL) and LDL particles.
  • Despite limitations, novel strategies targeting HDL are of significant interest.

Purpose of the Study:

  • To review current knowledge on novel recombinant HDL therapies.
  • To discuss the future prospects of these therapies in mitigating atherosclerotic CVD events.

Main Methods:

  • Investigation of recombinant HDL formulations, including apolipoprotein A-1 (apoA-1)-bound phospholipid disks, delipidated HDL particles, mutant apoA-1 proteins, and apoA-1 mimetic peptides.
  • Review of data from animal studies and some human trials.
  • Analysis of the potential of these therapies in clinical trials for atherosclerosis and CVD events.

Main Results:

  • Recombinant HDL formulations mimic the pre-beta fraction of native HDL, facilitating cholesterol efflux from macrophages.
  • Various formulations have been explored in preclinical and early clinical settings.
  • Further evaluation in large-scale clinical trials is necessary to establish efficacy in preventing CVD events.

Conclusions:

  • Novel recombinant HDL therapies represent a promising avenue for managing residual CVD risk.
  • These therapies aim to enhance cholesterol efflux and reduce atherosclerotic burden.
  • Clinical trials are essential to validate the therapeutic potential of recombinant HDL in preventing cardiovascular events.